​

IGM Biosciences (IGMS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

IGMS Stock Forecast

IGM Biosciences (IGMS) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $16.79, with a high of $31.00 and a low of $1.50. This represents a 1222.05% increase from the last price of $1.27.

- $7 $14 $21 $28 $35 High: $31 Avg: $16.79 Low: $1.5 Last Closed Price: $1.27

IGMS Stock Rating

IGM Biosciences stock's rating consensus is Hold, based on 18 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (44.44%), 10 Hold (55.56%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 18 0 10 8 Strong Sell Sell Hold Buy Strong Buy

IGMS Price Target Upside V Benchmarks

TypeNameUpside
StockIGM Biosciences1222.05%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$8.17
Last Closing Price$1.27$1.27$1.27
Upside/Downside--543.31%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Aug, 25--4--4
Jul, 25--4-15
Jun, 25--4-15
May, 25--5117
Apr, 25--71-8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 10, 2025Asthika GoonewardeneTruist Financial$2.00$2.09-4.31%57.48%
Jan 10, 2025Brian AbrahamsRBC Capital$1.50$2.09-28.23%18.11%
Dec 05, 2024Etzer DaroutBMO Capital$21.00$9.46121.99%1553.54%
Oct 01, 2024Brian AbrahamsRBC Capital$17.00$16.542.78%1238.58%
Oct 01, 2024Stephen WilleyStifel Nicolaus$25.00$14.0877.56%1868.50%
Oct 01, 2024Asthika GoonewardeneTruist Financial$12.00$16.54-27.45%844.88%
Aug 15, 2024Robert DriscollWedbush$25.00$8.72186.70%1868.50%
Aug 14, 2024Michael UlzMorgan Stanley$12.00$8.7237.61%844.88%
May 09, 2024Brian AbrahamsRBC Capital$20.00$9.34114.13%1474.80%
Aug 23, 2022Truist Financial$37.00$19.5389.45%2813.39%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 10, 2025JefferiesHolddowngrade
Jan 10, 2025GuggenheimNeutraldowngrade
Jan 10, 2025RBC CapitalOutperformSector Performdowngrade
Jan 10, 2025Morgan StanleyOverweightUnderweightdowngrade
Jan 09, 2025BMO CapitalOutperformMarket Performdowngrade
Dec 05, 2024BMO CapitalOutperforminitialise
Oct 01, 2024WedbushOutperformOutperformhold
Oct 01, 2024RBC CapitalOutperformOutperformhold
Sep 05, 2024RBC CapitalUnderperformUnderperformhold
Aug 15, 2024WedbushNeutralNeutralhold

Financial Forecast

EPS Forecast

$-20 $-14 $-8 $-2 $4 $10 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-5.16$-4.71$-3.24----
Avg Forecast$-5.66$-4.57$-3.19$-0.95$-0.64$-0.82$-0.69
High Forecast$-0.25$-4.44$-3.10$-0.09$0.05$9.81$0.06
Low Forecast$-11.19$-4.63$-3.28$-2.02$-1.66$-15.53$-1.80
Surprise %-8.83%3.06%1.57%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.07M$2.13M$2.68M----
Avg Forecast$899.50K$2.33M$2.63M$6.16M$10.74M$21.10M$53.37M
High Forecast$1.58M$2.87M$3.46M$13.72M$23.90M$46.95M$118.75M
Low Forecast$237.56K$1.89M$2.12M$1.01M$1.77M$3.47M$8.79M
Surprise %18.84%-8.77%1.98%----

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-214.25M$-246.42M$-195.79M----
Avg Forecast$-295.88M$-237.34M$-167.00M$-80.91M$-18.44M$1.33M$-36.30M
High Forecast$-12.82M$-232.38M$-162.27M$-4.67M$2.88M$513.04M$3.12M
Low Forecast$-585.19M$-242.31M$-171.73M$-105.93M$-86.74M$-812.32M$-94.11M
Surprise %-27.59%3.82%17.24%----

IGMS Forecast FAQ

Is IGM Biosciences stock a buy?

IGM Biosciences stock has a consensus rating of Hold, based on 18 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 10 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that IGM Biosciences is a neutral investment for most analysts.

What is IGM Biosciences's price target?

IGM Biosciences's price target, set by 18 Wall Street analysts, averages $16.79 over the next 12 months. The price target range spans from $1.5 at the low end to $31 at the high end, suggesting a potential 1222.05% change from the previous closing price of $1.27.

How does IGM Biosciences stock forecast compare to its benchmarks?

IGM Biosciences's stock forecast shows a 1222.05% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for IGM Biosciences over the past three months?

  • August 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • July 2025: 0% Strong Buy, 0% Buy, 80.00% Hold, 0% Sell, 20.00% Strong Sell.
  • June 2025: 0% Strong Buy, 0% Buy, 80.00% Hold, 0% Sell, 20.00% Strong Sell.

What is IGM Biosciences’s EPS forecast?

IGM Biosciences's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.95, marking a -70.68% decrease from the reported $-3.24 in 2024. Estimates for the following years are $-0.64 in 2026, $-0.82 in 2027, and $-0.69 in 2028.

What is IGM Biosciences’s revenue forecast?

IGM Biosciences's average annual revenue forecast for its fiscal year ending in December 2025 is $6.16M, reflecting a 130.11% increase from the reported $2.68M in 2024. The forecast for 2026 is $10.74M, followed by $21.1M for 2027, and $53.37M for 2028.

What is IGM Biosciences’s net income forecast?

IGM Biosciences's net income forecast for the fiscal year ending in December 2025 stands at $-80.915M, representing a -58.67% decrease from the reported $-196M in 2024. Projections indicate $-18.441M in 2026, $1.33M in 2027, and $-36.304M in 2028.